Sp42
ENGINEERED PROBIOTICS TO DELIVER THERAPEUTICS
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
The gut microbiome is implicated in a wide range of physiological processes, and holds great, but unrealized, potential for disease treatment and prevention. In this session, rising investigators demonstrate novel biotherapeutic applications of gut microbes, and how the intestinal bacterial community interacts with an arm of the innate immune system. The talks span the topics of bioengineered probiotics, anti-tumor activities of gut microbes, and introduce the complement system in the gut as an effector of antimicrobial defense.
The gut microbiome is implicated in a wide range of physiological processes, and holds great, but unrealized, potential for disease treatment and prevention. In this session, rising investigators demonstrate novel biotherapeutic applications of gut microbes, and how the intestinal bacterial community interacts with an arm of the innate immune system. The talks span the topics of bioengineered probiotics, anti-tumor activities of gut microbes, and introduce the complement system in the gut as an effector of antimicrobial defense.
Presenter
Tracks
Related Products
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
ACTIVATING TRANSCRIPTION FACTOR 6 ACCELERATES MICROBIOTA-DEPENDENT RISK FOR COLITIS-ASSOCIATED CANCER IN INFLAMMATORY BOWEL DISEASES
BACKGROUND AND AIMS: Chemoresistance is a major cause of colorectal cancer (CRC) recurrence and death. The critical role of gut microbiome in the efficacy of CRC chemotherapy remains unclear…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
